Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study)
Journal of Diabetes Investigation Jun 23, 2019
Miura H, et al. - Researchers investigated the impacts of the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, ipragliflozin, including those on appetite-regulating hormones, in individuals with suboptimally controlled type 2 diabetes in order to explore whether SGLT-2 inhibitors could increase appetite by affecting related hormones. The study sample consisted of 96 patients with a body mass index of ≥22 kg/m2 who were treated with ipragliflozin (50 mg/day) for 16 weeks. After treatment for 16 weeks, both glycated hemoglobin level and body weight were significantly reduced. The results obtained from the present prospective, multicenter, open-label study indicate that ipragliflozin improved glycemic control and reduced body weight, but also reduced serum leptin levels and may have increased appetite as a result.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries